|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:affiliatedWith
|
benzodiazepine
|
|
gptkbp:approvedBy
|
gptkb:FDA
1981
|
|
gptkbp:ATCCode
|
N05BA12
|
|
gptkbp:availableOn
|
gptkb:tablet
oral solution
extended-release tablet
|
|
gptkbp:brand
|
alprazolam
|
|
gptkbp:chemicalFormula
|
C17H13ClN4
|
|
gptkbp:contraindication
|
acute narrow-angle glaucoma
concurrent use with itraconazole
concurrent use with ketoconazole
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:discoveredBy
|
gptkb:Upjohn_Company
|
|
gptkbp:eliminationHalfLife
|
11 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:genericName
|
alprazolam
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xanax
|
|
gptkbp:interactsWith
|
gptkb:beer
opioids
other CNS depressants
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseSymptoms
|
confusion
death
coma
impaired coordination
|
|
gptkbp:patent
|
1971
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:riskFactor
|
cognitive impairment
overdose
suicidal ideation
respiratory depression
dependence
motor impairment
abuse potential
paradoxical reactions
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
addiction
fatigue
drowsiness
impaired coordination
memory impairment
withdrawal symptoms
|
|
gptkbp:usedFor
|
gptkb:panic_disorder
anxiety disorders
|
|
gptkbp:bfsParent
|
gptkb:Alprazolam
|
|
gptkbp:bfsLayer
|
7
|